# POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

> **NCT01051817** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 73 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis
- RRMS

## Interventions

- **DRUG:** AIN457
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01051817
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2015-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051817, "POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01051817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*